We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

52 hedge funds and large institutions have $361M invested in Entrada Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 6

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

11% more funds holding

Funds holding: 47 → 52 (+5)

8% more capital invested

Capital invested by funds: $334M → $361M (+$26.9M)

3.45% less ownership

Funds ownership: 78.69% → 75.24% (-3.4%)

Holders
52
Holders Change
+5
Holders Change %
+10.64%
% of All Funds
0.83%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
9
Increased
24
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Millennium Management
Millennium Management
New York
+$2.1M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.13M
3
Jane Street
Jane Street
New York
+$793K
4
CA
CHI Advisors
New York
+$753K
5
HF
HRT Financial
New York
+$513K

Top Sellers

1
Goldman Sachs
Goldman Sachs
New York
-$4.74M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$407K
3
RG
Redmile Group
California
-$300K
4
E
Ergoteles
New York
-$190K
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$164K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$70.6M – – –
MAM
2
MPM Asset Management
Massachusetts
$64.2M – – –
5VM
3
5AM Venture Management
California
$63.9M – – –
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$43.3M -$407K -30,514 -1%
RG
5
Redmile Group
California
$26.6M -$300K -22,500 -1%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$14.7M +$54.8K +4,102 +0.4%
Vanguard Group
7
Vanguard Group
Pennsylvania
$13.5M +$112K +8,412 +0.9%
SG
8
StepStone Group
California
$11M – – –
TCM
9
TCG Crossover Management
California
$8.48M – – –
Fidelity Investments
10
Fidelity Investments
Massachusetts
$7.71M +$367K +27,497 +5%
7IH
11
72 Investment Holdings
Connecticut
$7.38M – – –
BlackRock
12
BlackRock
New York
$3.07M +$320K +23,991 +13%
LCM
13
Laurion Capital Management
New York
$2.89M – – –
Millennium Management
14
Millennium Management
New York
$2.86M +$2.1M +157,359 +394%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$2.85M +$1.13M +84,716 +76%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.66M +$24.5K +1,833 +1%
MCM
17
Moore Capital Management
New York
$1.52M – – –
Charles Schwab
18
Charles Schwab
California
$1.3M +$6.78K +508 +0.6%
Jane Street
19
Jane Street
New York
$1.07M +$793K +59,374 +409%
NFGH
20
Nan Fung Group Holdings
Hong Kong
$1.07M – – –
State Street
21
State Street
Massachusetts
$936K +$721 +54 +0.1%
Citigroup
22
Citigroup
New York
$899K +$147K +10,981 +22%
TD Asset Management
23
TD Asset Management
Ontario, Canada
$865K – – –
CA
24
CHI Advisors
New York
$817K +$753K +56,374 New
Manulife (Manufacturers Life Insurance)
25
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$692K +$86.9K +6,506 +16%
1
2 3

TRDA Hedge Fund Activity: Q1 2023 in Review

52 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q1 2023, worth a combined $361M — up 8% from $334M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new TRDA positions and 4 closed out — a net gain of 5 holders — while 24 added to existing stakes and 6 trimmed.

The largest buyer was Millennium Management, adding an estimated $2.1M. The largest seller was Goldman Sachs, cutting an estimated $4.74M.

  • 52 institutional investors held Entrada Therapeutics (TRDA) as of Q1 2023, up from 47 in Q4 2022.
  • Funds reported $361M of Entrada Therapeutics stock for Q1 2023, up 8% quarter-over-quarter.
  • 9 funds opened new Entrada Therapeutics positions in Q1 2023 and 4 closed out, a net change of +5 holders.
  • The largest Entrada Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $2.1M added.
  • The largest Entrada Therapeutics seller in Q1 2023 was Goldman Sachs, an estimated $4.74M sold.

Based on aggregated 13F filings for Q1 2023.